Keyphrases
Breast Cancer
92%
Human Epidermal Growth Factor Receptor 2 (HER2)
68%
Metastatic Breast Cancer
66%
Overall Survival
62%
Progression-free Survival
43%
Denmark
41%
Advanced Breast Cancer
40%
Breast Cancer Patients
40%
Confidence Interval
38%
Breast Cancer Recurrence
34%
Trastuzumab
33%
HER2-positive Metastatic Breast Cancer
32%
Median Overall Survival
29%
Median Progression-free Survival
28%
Pertuzumab
23%
Brain Metastases
23%
Population-based
23%
Dual Blockade
23%
Biosimilar
23%
Hazard Ratio
17%
ER +
17%
Breast Cancer Diagnosis
15%
National Registry
15%
Treatment Line
15%
Chemotherapy
14%
Population-based Observational Studies
13%
Copenhagen
13%
Targeted Treatment
12%
Metastatic Triple-negative Breast Cancer
11%
Meta-analysis
11%
National Health Registry
11%
Aromatase Inhibitors
11%
Cancer Population
11%
Non-interventional Study
11%
Palbociclib
11%
Treatment Regimen
11%
Locally Advanced Breast Cancer
11%
Gemcitabine
11%
Registry Study
11%
Recurrent Ovarian Cancer
11%
Advanced Triple-negative Breast Cancer
11%
Capecitabine Monotherapy
11%
HER2-positive
11%
Stereotactic Radiosurgery
11%
Prognostic Value
11%
Breast Cancer Genomics
11%
Early Breast Cancer
11%
Development Validation
11%
Machine Learning Models
11%
Staging System
11%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Metastatic Breast Cancer
85%
Overall Survival
63%
Progression Free Survival
58%
Trastuzumab
33%
Chemotherapy
27%
Observational Study
25%
Gamma Urogastrone
23%
Biosimilar Agent
23%
Pertuzumab
21%
Epidermal Growth Factor Receptor 2
21%
Brain Metastasis
20%
Monotherapy
17%
Disease
16%
Combination Therapy
16%
Estrogen Receptor
15%
Paclitaxel
14%
Retrospective Study
13%
Palbociclib
11%
Aromatase Inhibitor
11%
Gemcitabine
11%
Capecitabine
11%
Receptor
11%
Ovary Cancer
11%
Fulvestrant
11%
Atezolizumab
11%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
11%
C Reactive Protein
11%
Recurrent Disease
11%
Neoplasm
8%
Medicine and Dentistry
Breast Cancer
85%
Metastatic Breast Cancer
69%
Overall Survival
47%
Progression Free Survival
33%
Epidermal Growth Factor Receptor 2
24%
Gamma Urogastrone
23%
Disease
20%
Trastuzumab
17%
Monotherapy
17%
Targeted Therapy
17%
Observational Study
16%
Estrogen Receptor
15%
Hazard Ratio
12%
Capecitabine
12%
Ovarian Cancer
12%
Meta-Analysis
11%
Systematic Review
11%
Brain Metastasis
11%
Assessment of Humans
11%
Recurrent Ovarian Cancer
11%
Stereotactic Radiosurgery
11%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
11%
Cancer Diagnosis
11%
Retrospective Study
11%
Breast Cancer Screening
11%
C Reactive Protein
11%
Cohort Analysis
11%
Neoadjuvant Chemotherapy
11%
Triple Negative Breast Cancer
11%
Biosimilar
11%
Gemcitabine
11%
Aromatase Inhibitor
11%
Palbociclib
11%
Fulvestrant
11%
Pertuzumab
10%
Receptor
9%
Malignant Neoplasm
9%
Carboplatin
6%
Doxorubicin
6%
Oncology
5%
Spine
5%
Paclitaxel
5%